Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 3/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12508251 | 0.87 | KIT (0.46) | TRPV1CA12CA2CA9DEGS1 | |
| SCHEMBL12508834 | 0.87 | TRPV1 (0.48) | TRPV1CA12CA2CA9DEGS1 | |
| SCHEMBL12508960 | 0.83 | CA12 (0.44) | TRPV1CA12CA2CA9DEGS1 | |
| SCHEMBL12508665 | 0.82 | CA12 (0.43) | TRPV1CA12CA2CA9DEGS1 | |
| SCHEMBL12508664 | 0.81 | AKR1C3 (0.43) | TRPV1CA12CA2CA9AKR1C3 | |
| SCHEMBL12508258 | 0.78 | KDM4E (0.42) | CA12CA2CA9AKR1C3RAB9A | |
| SCHEMBL12508662 | 0.77 | TRPV1 (0.55) | TRPV1CA12CA2CA9RAB9A | |
| SCHEMBL12508954 | 0.75 | MAPT (0.47) | TRPV1CA12CA2CA9AKR1C3 | |
| SCHEMBL12508958 | 0.73 | GRIN2D (0.53) | CA12CA2CA9AKR1C3RAB9A | |
| SCHEMBL12508257 | 0.71 | GRIN2D (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172415-A1 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7935706-B2 | Nitrogen-containing heterocycle derivatives substituted with cyclic group | SHIONOGI & CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7935706-B2 | Nitrogen-containing heterocycle derivatives substituted with cyclic group | SHIONOGI & CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090062261-A1 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062261-A1 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP | SHIONOGI & CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172415-A1 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP | NR4A1, NR0B2, NR0B1 | TRPV1 1332/4885CA12 1849/4885CA2 1032/4885 |
| US-20090062261-A1 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP | NR4A1, NR0B2, NR0B1 | TRPV1 1332/4885CA12 1849/4885CA2 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.